Back to Results

Alumis Inc (ALMS)

Alumis Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune disorders. Its pipeline includes envudeucitinib, a TYK2 inhibitor being studied for plaque psoriasis and systemic lupus erythematosus; A-005, a CNS-penetrant allosteric TYK2 inhibitor in Phase 1 for neuroinflammatory and neurodegenerative diseases; lonigutamab, a monoclonal antibody targeting IGF-1R for thyroid eye disease; and programs directed at interferon regulatory factor 5 to address immune dysfunction. The company was previously known as Esker Therapeutics, Inc. and adopted the Alumis name in January 2022. Incorporated in 2021, Alumis is headquartered in South San Francisco, California, and its common stock trades on NASDAQ under the symbol ALMS.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-ALMS
$7.13
-8.3% Downside
Fair
$32.13
313.4% Upside
Bargain
Weak
0.0%
November 12, 2026
2.2x
135.9x
1.006 B
539.8 M
3.5%
75.1%
1.1
80.1%
Valuation • Fair Value

Alumis Inc (NASDAQ-ALMS) Fair Value by Valuation Model

Review the available estimates for Alumis Inc (NASDAQ-ALMS), including Comps Fair Value.

Primary Valuation Read

Fair Value

$7.13

Estimated downside of 8.3% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

Comps Fair Value

$7.13

Comparable-company valuation reference.

Analyst Price Target

$32.13

Analysts imply upside of 313.4%.

How to read these valuation models

Use the 4 available valuation references for Alumis Inc (NASDAQ-ALMS) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Alumis Inc (NASDAQ-ALMS)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

7.398 M

Current operating scale indicator.

Revenue Forecast

6.6 M

Forward revenue estimate.

EBITDA

-421.4 M

Current operating profitability reference.

EBITDA Forecast

-422 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Alumis Inc (NASDAQ-ALMS) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Alumis Inc (NASDAQ-ALMS)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

1

Weak quality score that deserves closer review.

Altman Z-Score

1.1

Lower score that deserves closer risk review.

FCF / Net Income

80.1%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Alumis Inc (NASDAQ-ALMS). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Alumis Inc (NASDAQ-ALMS)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 12, 2026

Days to Earnings

55

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Alumis Inc (NASDAQ-ALMS), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Alumis Inc (NASDAQ-ALMS) Stock Forecast & Technical Outlook

Review Alumis Inc (NASDAQ-ALMS) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Buy

The 15-minute technical read for Alumis Inc (NASDAQ-ALMS) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Alumis Inc (NASDAQ-ALMS) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Alumis Inc (NASDAQ-ALMS) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Alumis Inc (NASDAQ-ALMS) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Alumis Inc (NASDAQ-ALMS) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Alumis Inc (NASDAQ-ALMS)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Alumis Inc (NASDAQ-ALMS) has a Strong Buy consensus, with 8 buy, 1 hold and 0 sell recommendations in the current data set.

Buy 8
Hold 1
Sell 0
FAQ • Fast Investor Answers

Alumis Inc (NASDAQ-ALMS) Stock FAQ

Data-supported answers about Alumis Inc (NASDAQ-ALMS), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$7.13
Estimated downside 8.3%
Valuation Rating
Overvalued
Estimated downside of 8.3%
Analyst Target
$32.13
Implied upside 313.4%
Financial Health
Weak
Current financial-health read

The current fair value estimate for Alumis Inc (NASDAQ-ALMS) is $7.13. This implies an estimated downside of 8.3% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 8.3% versus the current market price.

The available analyst price target for Alumis Inc (NASDAQ-ALMS) is $32.13. The analyst target implies estimated upside of 313.4%.

The current financial health read for Alumis Inc (NASDAQ-ALMS) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Alumis Inc (NASDAQ-ALMS) is November 12, 2026.

The latest available data indicates no current dividend yield for Alumis Inc (NASDAQ-ALMS).

The current market capitalization listed for Alumis Inc is 1.006 B.

The current enterprise value listed for Alumis Inc is 539.8 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Alumis Inc is NASDAQ-ALMS, and the stock is listed on NASDAQ.

Alumis Inc (NASDAQ-ALMS) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Alumis Inc is 3.5%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Alumis Inc is 75.1%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

LLY NYSE Eli Lilly and Company Fair Value Fair Market Cap 1,027.7 B
JNJ NYSE Johnson & Johnson Fair Value Fair Market Cap 650.6 B
MRK NYSE Merck & Company Inc Fair Value Fair Market Cap 362.4 B
NVS NYSE Novartis AG ADR Fair Value Fair Market Cap 266.2 B
NVO NYSE Novo Nordisk A/S Fair Value Bargain Market Cap 191.3 B
PFE NYSE Pfizer Inc Fair Value Fair Market Cap 157.7 B
BMY NYSE Bristol-Myers Squibb Company Fair Value Fair Market Cap 128.8 B
SNY NASDAQ Sanofi ADR Fair Value Undervalued Market Cap 101.9 B
GSK NYSE GSK plc DRC Fair Value Undervalued Market Cap 100.8 B
TAK NYSE Takeda Pharmaceutical Co Ltd ADR Fair Value Fair Market Cap 60.801 B
TEVA NYSE Teva Pharma Industries Ltd ADR Fair Value Fair Market Cap 45.423 B
HLN NYSE HALEON PLC ADR Fair Value Fair Market Cap 40.198 B
RPRX NASDAQ Royalty Pharma Plc Fair Value Fair Market Cap 33.653 B
ZTS NYSE Zoetis Inc Fair Value Bargain Market Cap 29.504 B
VTRS NASDAQ Viatris Inc Fair Value Undervalued Market Cap 19.446 B
JAZZ NASDAQ Jazz Pharmaceuticals PLC Fair Value Fair Market Cap 15.628 B
CORT NASDAQ Corcept Therapeutics Incorporated Fair Value Fair Market Cap 11.943 B
ELAN NYSE Elanco Animal Health Fair Value Fair Market Cap 11.202 B
AXSM NASDAQ Axsome Therapeutics Inc Fair Value Fair Market Cap 10.884 B
RDY NYSE Dr. Reddy’s Laboratories Ltd ADR Fair Value Fair Market Cap 10.161 B